BOTULINUM TOXIN FOR TREATING POSTHERPETIC NEURALGIA

• US 20090041805A1
• Filed: 10/04/2006
• Published: 02/12/2009
• Est. Priority Date: 12/05/2000
• Status: Active Grant

• Current Assignee: Allergan Incorporated (Abbvie Incorporated)
• Original Assignee: Allergan Incorporated (Abbvie Incorporated)
• Inventors: WALKER, PATRICIA S.
• Granted Patent: US 7,479,281 B1
• Time in Patent Office: Days
• US Class Current: 424/239.100
• CPC Class Codes: A61K 38/4893 Botulinum neurotoxin (3.4.24.69)
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 13/10 of the bladder
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: C07K 14/33 from Clostridium (G)

Abstract

Methods for treating conditions in an animal or human subject. The conditions may be pain, skeletal muscle conditions, smooth muscle conditions, glandular conditions and cosmetic conditions. The methods comprise the step of administering a Clostridium neurotoxin component or Clostridium neurotoxin component encoding DNA to the subject using a needleless syringe.

Claims

1-35. -35. (canceled)

36. A method for treating pain associated with postherpetic neuralgia in a patient in need thereof, the method comprising the step of locally administering a therapeutically effective amount of a botulinum toxin in powder form to a patient using a needleless injector, wherein the pain associated with the postherpetic neuralgia is thereby alleviated within 1 to 7 days of the local administration of the botulinum toxin to the patient.

37. The method of claim 36, wherein the needless injector has an elongated tubular nozzle and the needleless injector is connected to or connectable to means for producing a gas flow.

38. The method of claim 37, wherein means for producing gas flow is an energizing means.

39. The method of claim 37, wherein the gas flow is supersonic.

40. The method of claim 38, wherein the energizing means is a compressed gas tank containing an inert compressed gas.

41. The method of claim 40, wherein the inert compressed gas is helium.

42. The method of claim 36, wherein the botulinum toxin is administered with a carrier made of a solid material, the solid material selected from the group consisting of gold, platinum, tungsten and an ice crystal.

43. The method of claim 36, wherein the pain associated with postherpetic neuralgia is localized to an abdominal region of the patient.

44. The method of claim 36, wherein the botulinum toxin is selected from the group consisting of botulinum toxin type A, B, C₁, D, E, F and G.

45. A method for treating pain associated with postherpetic neuralgia in a patient in need thereof, the method comprising the step of locally administering a therapeutically effective amount of botulinum toxin type A or B in powder form intradermally to a patient using a needleless injector connected to or connectable to means for producing a supersonic gas flow, wherein the pain associated with the postherpetic neuralgia is thereby alleviated within 1 to 7 days.

46. The method of claim 45, wherein a duration of pain alleviation is provided that lasts from about 7 to about 27 months.

47. The method of claim 45, wherein pain associated with postherpetic neuralgia is in the thorax of the patient.

48. The method of claim 45, wherein pain associated with postherpetic neuralgia is localized to the abdomen of the patient and the step of locally administering the botulinum toxin is to the abdomen of the patient.

49. The method of claim 45, wherein the therapeutically effective amount of the botulinum toxin type A administered to the patient is between about 0.05 U/kg to about 2 U/kg.

50. A method for treating pain associated with postherpetic neuralgia in a patient in need thereof, the method comprising the step of administering locally a therapeutically effective amount of botulinum toxin type A in powder form, using a needleless injector connected to or connectable to energizing means for producing a supersonic gas flow to a patient having healed lesions and pain localized to an abdominal region, wherein administration of the therapeutically effective amount of botulinum toxin type A in powder form is intradermal and into the abdominal region, wherein pain localized to the abdominal region is thereby alleviated within 1 to 7 days of the local administration of the botulinum toxin.

51. The method of claim 50, wherein the botulinum toxin is administered with a carrier made of a solid material, wherein the solid material is selected from the group consisting of gold, platinum, tungsten and an ice crystal.

52. The method of claim 51, wherein the carrier has a diameter less than about 10 millimeters.

53. The method of claim 50, wherein a duration of the pain alleviation is provided that last from about 7 to about 27 months.